Analysts Have Conflicting Sentiments on These Healthcare Companies: Galectin Therapeutics (NASDAQ: GALT), Summit Therapeutics (NASDAQ: SMMT) and DENTSPLY SIRONA Inc (NASDAQ: XRAY)

By Austin Angelo

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Galectin Therapeutics (NASDAQ: GALT), Summit Therapeutics (NASDAQ: SMMT) and DENTSPLY SIRONA Inc (NASDAQ: XRAY).

Galectin Therapeutics (NASDAQ: GALT)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Galectin Therapeutics (NASDAQ: GALT) today and set a price target of $10. The company’s shares closed yesterday at $1.54.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 18.5% and a 42.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, Madrigal Pharmaceuticals Inc, and Aviragen Therapeutics Inc.

Galectin Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $7.50.

Summit Therapeutics (NASDAQ: SMMT)

H.C. Wainwright analyst Debjit Chattopadhyay assigned a Buy rating to Summit Therapeutics (NASDAQ: SMMT) today and set a price target of $16. The company’s shares closed yesterday at $11.45.

According to TipRanks.com, Chattopadhyay is a 1-star analyst with an average return of -0.2% and a 43.7% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Strongbridge Biopharma Plc, and Ionis Pharmaceuticals Inc.

Summit Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $22.67.

DENTSPLY SIRONA Inc (NASDAQ: XRAY)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on DENTSPLY SIRONA Inc (NASDAQ: XRAY), with a price target of $68. The company’s shares closed yesterday at $65.50.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -18.6% and a 26.3% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as RegeneRx Biopharmaceuticals Inc, Biospecifics Technologies Corp, and Synergy Pharmaceuticals Inc.

DENTSPLY SIRONA Inc has an analyst consensus of Strong Buy, with a price target consensus of $72.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.